Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early switch from tyrosine kinase inhibitor to nivolumab in metastatic renal cell carcinoma
2016-002170-13Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in clear cell renal cell carcinoma (ccRCC), renal cell carcinoma (RCC) and metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by AIO-Studien. Primary endpoint: overall survival. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)renal cell carcinoma (RCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2016-002170-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002170-13.